9.3 Gastrointestinal & Hepatic Conditions

9.3 Gastrointestinal & Hepatic Conditions

Quick Answer: Treat GORD with lifestyle plus PPI at the lowest effective dose and a step-down plan; support full H. pylori multi-drug adherence; monitor and counsel IBD therapies safely; climb the constipation ladder rationally; choose antiemetics by cause; and in hepatic impairment, adjust high-risk drugs, use paracetamol cautiously with dose limits, and address alcohol. Verify doses and cautions in AMH.

GI and hepatic topics integrate assessment (red flags for cancer, bleeding, obstruction), implementation of common community regimens, and monitoring for adverse effects (Competencies 3.1–3.3).

GORD — PPI use and step-down

Gastro-oesophageal reflux disease ranges from intermittent heartburn to erosive oesophagitis and extra-oesophageal symptoms. Pharmacists see large volumes of proton pump inhibitors (e.g. omeprazole, esomeprazole, pantoprazole, rabeprazole, lansoprazole).

Rational PPI use

• Confirm indication: symptomatic GORD, peptic ulcer healing, H. pylori regimens, gastroprotection with high-risk NSAID users, or specialist indications
• Prefer once-daily morning dosing before food for many PPIs (product-specific)
• Use the lowest effective dose for the shortest appropriate duration after healing/control
• Review long-term PPI: many patients remain on high-dose therapy without reassessment

Step-down concepts

After control of uncomplicated GORD symptoms:

1. Reduce to lowest effective daily dose
2. Consider intermittent or on-demand strategies where clinically appropriate
3. Trial cessation with lifestyle measures if suitable
4. Do not abruptly abandon PPIs in patients with severe erosive disease, Barrett’s surveillance pathways, or high-risk ulcer history without medical planning

Lifestyle counselling remains foundational: weight management if overweight, head-of-bed elevation for night symptoms, avoid late large meals, limit trigger foods/alcohol, and review medicines that worsen reflux (e.g. some calcium channel blockers, nitrates, anticholinergics — individualise).

PPI safety awareness

Long-term PPI associations discussed in practice include nutrient issues (e.g. magnesium, B12 in some contexts), infection risk signals (C. difficile, community pneumonia associations in literature), and bone risk debates — interpret with clinical balance, not scaremongering. Interact with drugs needing acidic absorption (e.g. some antifungals/antivirals — check AMH). Rebound acid hypersecretion can occur after stopping long-term PPI; counsel temporary symptom return and medical review rather than immediate lifelong restart without assessment.

Red flags (medical review, not endless OTC escalation): dysphagia, odynophagia, GI bleeding signs, unexplained weight loss, persistent vomiting, iron-deficiency anaemia, age-related new dyspepsia pathways — follow local referral rules.

Helicobacter pylori — adherence is the therapy

Eradication regimens combine acid suppression (usually a PPI) with two or more antimicrobials (and sometimes bismuth in certain regimens) for a defined multi-day course. Exact first-line combinations evolve with resistance — open-book AMH/guidelines for the current preferred regimen.

Pharmacist priorities:

• Explain that all components must be taken for the full duration; partial courses fail and breed resistance
• Map timing with meals/PPI timing as per product
• Warn about specific toxicities: metronidazole–alcohol reaction risk; clarithromycin interactions (CYP3A4); amoxicillin allergy; tetracycline–dairy/chelation issues when used
• Anticipate GI upset and reinforce persistence unless severe toxicity occurs
• Confirm follow-up testing plans when indicated (e.g. urea breath test pathways after appropriate PPI washout)

Intern exam items often test recognition that adherence failure — not “weak PPI brand” — is the usual reason community eradication fails.

Inflammatory bowel disease medicines — high-level safety

Ulcerative colitis and Crohn’s disease therapies range from aminosalicylates to immunomodulators and biologics. Community pharmacists most often counsel mesalazine (5-ASA) and encounter thiopurines (azathioprine, mercaptopurine) on maintenance scripts.

Mesalazine

Used especially in ulcerative colitis (oral and/or rectal forms depending on disease distribution). Counselling:

• Formulation matters: do not crush/chew modified-release products unless product allows
• Rectal foam/enema/suppository technique for distal disease
• Headache, GI upset possible; rare renal and blood dyscrasia signals — report unexplained bruising, severe infection, or declining renal function context
• Adherence during remission prevents flares for many patients

Thiopurines (high-level monitoring)

Azathioprine and mercaptopurine suppress immune activity. Safety principles:

• Baseline and ongoing blood count and liver test monitoring per specialist protocols
• Infection risk — advise early review for fever/severe infection
• Pancreatitis and hepatotoxicity awareness (abdominal pain, jaundice, dark urine)
• Important interactions (e.g. allopurinol dramatically increases thiopurine toxicity — classic exam interaction)
• Sun protection counselling (skin cancer risk with long-term immunosuppression)
• Pregnancy planning requires specialist input

Do not authorise dose changes at the counter; escalate abnormal symptoms and missed monitoring.

Constipation ladder

Treat cause first: opioids, anticholinergics, iron, dehydration, immobility, low fibre, hypothyroidism, obstruction red flags.

Red flags: absolute constipation with vomiting/distension (obstruction), blood, weight loss, new severe symptoms in older adults — medical assessment.

Opioid-induced constipation often needs prophylactic softener/stimulant strategies rather than bulk alone.

Antiemetics — match mechanism to cause

Nausea/vomiting causes: gastroenteritis, medicines (opioids, chemotherapy, antibiotics), pregnancy, migraine, vestibular disease, bowel obstruction.

High-level community agents:

• Dopamine antagonists (e.g. metoclopramide, prochlorperazine) — extrapyramidal risk, especially young people; metoclopramide has duration limits for neurological risk; prochlorperazine sedation/hypotension awareness
• Serotonin (5-HT3) antagonists (e.g. ondansetron) — common in post-op/chemo and selected use; constipation and QT considerations
• Antihistamine/anticholinergic agents for motion/vestibular nausea — sedation, caution in elderly (falls, confusion)

Exclude red flags (severe dehydration, acute abdomen, head injury, chemotherapy protocols needing specialist plans). In pregnancy, prefer recognised safe pathways and medical advice — do not improvise novel combinations.

Hepatic impairment — dose caution principles

The liver metabolises many drugs; impairment increases exposure to high extraction-ratio agents, reduces clotting factor synthesis (bleeding risk with anticoagulants), and can precipitate encephalopathy with sedating medicines.

Pharmacist approach:

1. Identify known cirrhosis/hepatitis/alcohol-related disease
2. Check AMH hepatic dosing guidance before supply of narrow-index or highly metabolised drugs
3. Prefer safer alternatives when equivalent efficacy exists
4. Avoid unnecessary hepatotoxins and sedating constipating regimens that worsen encephalopathy risk
5. Coordinate with prescriber when laboratory synthetic function is poor (INR, bilirubin, albumin context)

Paracetamol in liver disease

Paracetamol remains a preferred simple analgesic/antipyretic in many patients with liver disease when dose is limited and monitored, because NSAIDs may be more hazardous (bleeding, renal, decompensation risks in cirrhosis). Principles:

• Do not use “standard maximum in everyone” without checking hepatic guidance — lower daily maxima often apply in chronic liver disease/malnutrition/chronic heavy alcohol use (confirm current AMH)
• Avoid duplicate paracetamol in combination cold products
• Counsel that intentional or accidental overdose is a medical emergency (N-acetylcysteine pathways)
• Never tell patients with cirrhosis that “paracetamol is always banned” or “always unrestricted” — the truth is cautious, dose-limited use under advice

Alcohol counselling

Alcohol worsens GORD, pancreatitis risk, hepatic injury, interacts with metronidazole (disulfiram-like reaction), potentiates sedatives, and destabilises INR control on warfarin. Offer brief intervention: ask, advise, assist referral to support services, and align medicine counselling with reduction goals. In alcohol withdrawal risk, do not improvise detox at the counter — medical pathways needed.

Exam mindset

Expect scenarios on PPI step-down, H. pylori full-course adherence, mesalazine formulation counselling, thiopurine–allopurinol danger, constipation ladder + red flags, antiemetic adverse effects, and paracetamol dose caution in hepatic impairment. Use AMH for numbers; use clinical reasoning for the safe plan.